Metastatic Adenocarcinoma of the Gastroesophageal Junction

DBCOND0069248Gastrointestinal Tract Disorders Neoplasms

Metastatic Adenocarcinoma of the Gastroesophageal Junction is the indication for 3 drugs in DrugBank. It is covered by 7 curated, structured indications.

Also known as: Metastatic Adenocarcinoma of the Gastro-Esophageal Junction · metastatic Adenocarcinomas of the Gastroesophageal Junction
Classified under: Gastrointestinal Tract Disorders
Neoplasms
Neoplasms, Glandular and Epithelial
Indicated drugs: Capecitabine
Pembrolizumab
Trastuzumab

What you can answer from here — as of October 23, 2026

3Indicated drugsWith each drug's targets and mechanism

Listed above

7Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

2Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Metastatic Adenocarcinoma of the Gastroesophageal Junction share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account